Q-omics provides the consensus-scored IL17F profile across patient tissues and cancer cell-line models. IL17F expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL17F is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, IL17F RNA expression shows 7,105 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where IL17F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17F survival associations across molecular data types. IL17F RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17F RNA expression–survival associations across cancer types. High IL17F expression shows unfavorable associations in ACC, UCEC, SCLC and SKCM, but favorable associations in HNSC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IL17F RNA expression.
This table summarizes IL17F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL17F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17F shows lower tumor expression in HNSC and KICH and higher tumor expression in LIHC, COAD and READ. The HNSC box plot shows higher IL17F RNA expression in normal versus tumor tissue (log2 FC = −0.590, t-test p < 0.001).
This table shows molecular features associated with IL17F in patient tissues and cancer cell lines. In patient samples, IL17F shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
